T he nucleus tractus solitarius (NTS) is the primary integrative center for cardiovascular control and other autonomic functions in the central nervous system. The NTS not only integrates convergent information but itself is the site of substantial modulation. Our previous studies demonstrated that several neuromodulators are involved in cardiovascular control in the NTS, including ATP, 1 adenosine, 1,2 angiotensin II, 3 angiotensin III, 4 nitric oxide, [5] [6] [7] carbon monoxide, 8 -11 and insulin. 12 Among these neuromodulators, adenosine has been shown to play an important role in central cardiovascular control. 1, 2, 13 Microinjection of adenosine into NTS produces slowly developed, long-lasting (minutes), and dose-related decreases in blood pressure (BP) and heart rate (HR). 2, 14 
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Adenosine acts as a neuromodulator at many levels of the central nervous system, including the brainstem, which is the central cardiovascular control center. 15, 16 The natural precursor of neuromodulator adenosine in the central nervous system is ATP, which is dephosphorylated and rapidly becomes adenosine via the activity of ectonucleotidases on synaptic release. 17 Among 4 adenosine receptor subtypes, the A 1 and A 2A receptor subtypes have been demonstrated to play neuromodulatory roles in the NTS. 15, 18, 19 The A 1 receptor is expressed in the central nervous system ubiquitously and has been shown to inhibit neuronal activity, whereas the A 2A receptor is expressed at high levels in limited regions of the brain that are primarily linked to adenylyl cyclase activation. 17, 20 In the NTS, activation of the A 1 and A 2A receptors has been demonstrated to elicit dose-related increases and decreases in BP, respectively. 14, 15 Together, these studies suggest that the cardiovascular modulatory effects of adenosine in the NTS are mediated predominantly by the A 2A receptor.
Studies including ours have demonstrated that the depressor and bradycardic effects of adenosine in the NTS were attenuated by a nitric oxide synthase (NOS) inhibitor. 7, 21 In addition, microinjection of nitric oxide (NO) donors into subpostremal NTS evokes a pattern of regional sympathetic responses that increases in preganglionic adrenal nerve activity and decreases in renal, postganglionic sympathetic nerve activity. Interestingly, these sympathetic responses are similar to those evoked by stimulation of the adenosine A 2A receptor in the NTS. 13 All of these results indicate that the cardiovascular modulatory effects of adenosine in the NTS might be accomplished by NOS activation and subsequent NO release; however, the underlying signal mechanism between adenosine receptor activation and NO production in the NTS remains unclear. Recently, it has been demonstrated that activation of the adenosine A 2A receptor can cause NO release in endothelial cells. 22, 23 In addition, it has been reported that adenosine induces endothelial NOS (eNOS) activation in a Ca 2ϩ -insensitive manner that involves extracellular signalregulated kinase (ERK) 1 and 2 phosphorylation in human umbilical vein endothelial cells. 24 This raises the possibility that the cardiovascular modulatory effects of adenosine in the NTS might be mediated through activation of ERK1/2 and eNOS.
In the present experiments, we tested whether adenosine could induce ERK1/2 and eNOS activation and whether specific ERK1/2 and eNOS inhibitors are able to inhibit the cardiovascular effects of adenosine in the NTS. In addition, we examined whether a specific ERK inhibitor could attenuate the eNOS activation induced by adenosine in the NTS. Our results suggest that a possible adenosine-ERK-eNOS signaling pathway is well regulated in the modulation of cardiovascular responses to adenosine in the NTS.
Methods

Experimental Chemicals
All experimental chemicals were purchased from Sigma-Aldrich (St Louis, Mo) except when otherwise noted. Chemicals microinjected into the NTS (eg, adenosine, PD98059, L-NIO, and vinyl-L-NIO) were dissolved in reduced-serum medium (Opti-MEM I; Invitrogen, Carlsbad, Calif).
Animals
Male Sprague-Dawley rats (weight 250 to 350 g) were obtained from the National Science Council Animal Facility (Taipei, Taiwan) and housed in the animal room of Kaohsiung Veterans General Hospital (Kaohsiung, Taiwan). The rats were kept in individual cages in a room where lighting was controlled (12-hour light/12-hour dark cycle), and temperature was maintained at 23°C to 24°C. The rats were given normal rat chow (Purina; St. Louis, Mo) and tap water ad libitum. All animal research protocols had been approved by the Research Animal Facility Committee of Kaohsiung Veterans General Hospital.
Intra-NTS Microinjection and Hemodynamic Measurements
Rats were anesthetized with urethane (1.0 g/kg IP and 0.3 g/kg IV if necessary). The preparation of animals for intra-NTS microinjection and the methods used to locate the NTS have been described previously. 5 Briefly, a polyethylene cannula was inserted into the femoral vein for fluid supplementation, and BP was measured via a femoral-artery cannula by pressure transducer and polygraph (Gould, Cleveland, Ohio). HR was monitored by a tachograph preamplifier (Gould). To verify that the needle tip of the glass electrode was exactly in the NTS, L-glutamate (0.154 nmol/60 nL) was microinjected. This would induce a characteristically abrupt decrease in BP (⌬BP Ն35 mm Hg) and HR (⌬HR Ն50 bpm) if the needle tip was located precisely in the NTS.
To investigate whether ERK 1 and ERK 2 participate in cardiovascular responses to adenosine in the NTS, 2 groups of rats (6 rats per group) received microinjection of adenosine (0.77 nmol/60 nL) in the unilateral NTS, and changes in BP and HR were measured. The rats were then allowed to rest for at least 30 minutes until BP and HR returned to basal levels. An MEK inhibitor, PD98059 (6 pmol/60 nL), or vehicle was microinjected into the NTS, then the same dose of adenosine (0.77 nmol) was microinjected into the NTS 10, 30, 60, and 90 minutes after PD98059 or vehicle administration. Cardiovascular parameters were recorded.
To investigate whether eNOS or neuronal NOS (nNOS) also participates in the cardiovascular responses to adenosine in the NTS, similar experimental procedures were performed to study the effects of pretreatment with a selective eNOS inhibitor, L-NIO (L-N 5 -(1-iminoethyl)-ornithine; Calbiochem, San Diego, Calif; 6 nmol/60 nL), and a specific nNOS inhibitor, vinyl-L-NIO (L-N 5 -(1-imino-3-butenyl)-ornithine; Alexis Biochemicals, San Diego, Calif; 600 pmol/60 nL), on the cardiovascular effects of adenosine in the NTS.
Western Blot Analysis
Four groups of rats (6 rats per group) were enrolled in this test. Rats received intra-NTS microinjection with vehicle, PD98059, or L-NIO, respectively, 10 minutes before adenosine injection; another group of rats received microinjection with the A 2A receptor agonist CGS21680 (24 pmol/60 nL). Ten to 20 minutes after adenosine injection, rats were euthanized, and brainstems were excised immediately. The NTS was dissected by a micropunch (1-mm inner diameter) from a brainstem slice 1 mm thick at the level of the obex under a microscope. Total protein extract was prepared by homogenization of the NTS in lysis buffer with protease inhibitor cocktail and phosphatase inhibitor cocktail and was incubated for 1 hour at 4°C. Protein extracts (20 g per sample assessed by BCA protein assay; Pierce) were subjected to 7.5% to 10% SDS-Tris glycerin gel electrophoresis and transferred to a polyvinylidene difluoride membrane (GE Healthcare, Buckingamshire, UK). The membrane was blocked with 5% nonfat milk in TBS/Tween 20 buffer (10 mmol/L Tris, 150 mmol/L NaCl, 0.1% Tween 20, pH 7.4), incubated with anti-p-ERK1/2 T202/Y204 antibody (Cell Signaling Technology, Danvers, Mass), anti-ERK1/2 antibody (Cell Signaling Technology), anti-p-eNOS S1177 antibody (Cell Signaling Technology), and antieNOS antibody (BD Biosciences, San Jose, Calif) at 1:1000 in PBST with 5% BSA, and incubated at 4°C overnight. Peroxidase-conjugated anti-mouse or anti-rabbit antibody (1:5000) was used as secondary antibody. The membrane was detected with an ECL-Plus detection kit (GE Healthcare) on film. The films were scanned by photo scanner (4490, Epson, Long Beach, Calif) and were analyzed with NIH Image densitometry analysis software (National Institutes of Health, Bethesda, Md).
Immunohistochemistry Analysis
Adenosine (0.77 nmol/60 nL) was administered into the NTS with or without PD98059 (6 nmol/60 nL) pretreatment. Ten to 20 minutes after adenosine microinjection, brainstems were excised and fixed with 4% formaldehyde. Paraffin-embedded serial sections were cut at 5-m thickness. The sections were dewaxed, quenched in 3% H 2 O 2 /methanol, antigen-retrieved in citric buffer (10 mmol/L, pH 6.0), blocked in 5% goat serum, and incubated with anti-phospho- 
Statistical Analysis
Group data are expressed as meanϮSEM. The paired Student t test (for comparisons of cardiovascular parameters before and after pretreatment), unpaired Student t test (for control and study group comparisons), or 1-way ANOVA with Scheffé post hoc comparison was applied to compare group differences. Differences with PϽ0.05 were considered significant.
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written.
Results
Effects of MEK Inhibitor on Cardiovascular Responses to Adenosine in the NTS
To assess whether ERK1 and ERK2 participates in the cardiovascular modulatory effects of adenosine in the NTS, we investigated the inhibitory effect of an MEK inhibitor, PD98059, on the cardiovascular effects of adenosine in the NTS. Microinjection of adenosine into unilateral NTS induced hypotension and bradycardia. The depressor effect of single-dose adenosine lasted for more than 5 minutes, and the bradycardic effect lasted for more than 15 minutes ( Figure  1A ). These results were consistent with our previous findings. 7, 8 Pretreatment with PD98059 did not elicit significant cardiovascular responses ( Figure 1A) . Interestingly, the depressor and bradycardic responses of the same dose of adenosine in the NTS were attenuated 10 minutes after PD98059 treatment (Ϫ37.9Ϯ2.9 versus Ϫ21.7Ϯ3.1 mm Hg and Ϫ78.6Ϯ13.2 versus Ϫ52.9Ϯ12.0 bpm, respectively; PϽ0.05, paired t test; nϭ6; Figure 1A and 1B). The cardiovascular effects of adenosine in the NTS recovered gradually 30 minutes after PD98059 treatment ( Figure 1A) . To clarify the specificity of the inhibitory effects of PD98059 in the NTS, we tested the effect of PD98059 on the cardiovascular response of L-glutamate in the NTS. The results revealed that pretreatment with PD98059 did not alter the depressor and bradycardic effects of L-glutamate (Data Supplement Figure  I ), which is the major neurotransmitter in the NTS.
Effects of eNOS Inhibitor and nNOS Inhibitor on Cardiovascular Responses to Adenosine in the NTS
Our previous studies suggested that cardiovascular modulatory responses to adenosine are accomplished through activation of NOS in the NTS. 7 To identify which constitutive NOS contributes to these cardiovascular responses to adenosine in the NTS, we investigated the effects of a selective eNOS inhibitor, L-NIO, and an nNOS-specific inhibitor, vinyl-L-NIO, on the cardiovascular responses induced by adenosine in the NTS. Ten minutes after L-NIO (6 nmol/60 nL) pretreatment, hypotensive and bradycardic responses to the same dose of adenosine were attenuated significantly (Ϫ36.0Ϯ1.7 versus Ϫ15.8Ϯ2.8 mm Hg and Ϫ79.3Ϯ7.7 versus Ϫ29.3Ϯ8.5 bpm, respectively; PϽ0.05; Figure 2A and 2B). As the effects of L-NIO washed out, the hypotensive and bradycardic effects of adenosine recovered (Figure 2A) . The almost 60% inhibition in adenosine-mediated hypotensive and bradycardic responses caused by the eNOS inhibitor L-NIO indicated that eNOS activity plays a role in the downstream signaling of adenosine. In contrast, pretreatment with vinyl-L-NIO (600 pmol/60 nL) did not diminish the depressor (Ϫ38.6Ϯ2.8 versus Ϫ38.2Ϯ2.7 mm Hg, PϾ0.05, nϭ6) and bradycardic effects (Ϫ84.6Ϯ12.4 versus Ϫ94.4Ϯ9.3 bpm, PϾ0.05, nϭ6) of adenosine in the NTS (Data Supplement Figure II) . These results indicate that nNOS did not play a role in adenosine-mediated hypotensive and bradycardic responses in the NTS.
Adenosine Induced eNOS Phosphorylation in the NTS
Using a specific pharmacological inhibitor, we demonstrated that eNOS but not nNOS was involved in the adenosinemediated hypotensive and bradycardic responses in the NTS. We further investigated whether adenosine may induce eNOS phosphorylation in the NTS. The phosphorylation of eNOS was determined by immunoblotting and immunohistochemistry staining with antibodies specifically against phosphoeNOS S1177 . The results of immunoblotting analysis demonstrated that adenosine could increase eNOS phosphorylation in the NTS (1.9Ϯ0.2 versus 1.0Ϯ0.3, PϽ0.05, nϭ6; Figure  3A and 3B). To confirm that intra-NTS adenosine administration induces eNOS phosphorylation, paraffin sections of the brainstem were subjected to immunohistochemistry staining. Immunohistochemistry stain against phospho-eNOS S1177 of the NTS revealed the adenosine-administered side had more phospho-eNOS S1177 -positive cells than the control side ( Figure 3C , frame c versus frame d). The immunohistochemistry results were consistent with those of immunoblotting.
Adenosine Induced ERK1/2 Phosphorylation in the NTS
PD98059 inhibited the depressor and bradycardic effects of adenosine in NTS, which suggested that ERK1 and ERK2 contribute to cardiovascular responses to adenosine in the NTS. We further investigated whether adenosine can induce ERK1/2 phosphorylation in the NTS. Phosphorylation of ERK1/2 was determined by immunoblotting and immunohistochemistry staining with an antibody specifically against phospho-ERK1/2 T202/Y204 . Immunoblotting analysis of protein extract of adenosine-treated NTS revealed that ERK1/2 phosphorylation was increased compared with that of the control group (1.8Ϯ0.1 versus 1.0Ϯ0.1 for ERK1 and 1.8Ϯ0.2 versus 1.0Ϯ0.1 for ERK2, PϽ0.05; nϭ6; Figure 4A and 4B). To confirm that adenosine induces ERK1/2 phosphorylation in situ, paraffin sections of the brainstem were subjected to immunohistochemistry staining analysis with phospho-ERK1/2 T202/Y204 antibodies. Figure 4C shows that there were more phospho-ERK1/2-positive neuronal cells in the NTS of the adenosine-administered side than in the control side (frame c versus frame d). The results of immunoblotting and immunohistochemistry staining were consistent and indicated that adenosine can induce ERK1/2 phosphorylation in situ.
MEK1/2 Inhibitor Attenuated Adenosine-Induced eNOS Phosphorylation in the NTS
To test whether ERK1/2 may induce eNOS phosphorylation, we investigated the inhibitory effect of PD98059 on eNOS phosphorylation in the NTS. The results from the immunoblotting analysis demonstrated that pretreatment with the MEK inhibitor PD98059 could attenuate adenosine-induced eNOS phosphorylation in the NTS (0.8Ϯ0.2 versus 1.9Ϯ0.2, PϽ0.01; Figure 3A and 3B). These results suggested that ERK-eNOS signaling served as the downstream molecules of adenosine-mediated cardiovascular responses in the NTS. This conclusion was further supported by the results of immunohistochemistry staining against phospho-eNOS S1177 , which demonstrated that the number of phospho-eNOSpositive cells on the PD98059-pretreated side was much less than on the vehicle-pretreated side ( Figure 3C , frame g versus frame h).
Adenosine Activates ERK1/2 and eNOS via the Adenosine A 2A Receptor in the NTS
It was reported that the cardiovascular modulatory effects of adenosine in the NTS are mediated predominantly through the A 2A receptor. The above results demonstrated that adenosine could induce ERK1/2 and eNOS phosphorylation in the NTS. Therefore, we tested whether the induction of ERK1/2 and eNOS phosphorylation is via the adenosine A 2A receptor in the NTS. Immunoblotting of NTS treated with the A 2A agonist CGS21680 revealed increases in ERK1/2 phosphorylation (2.1Ϯ0.5 versus 1.0Ϯ0.4 for ERK1 and 2.0Ϯ0.1 versus 1.0Ϯ0.2 for ERK2, PϽ0.05; nϭ6; Figure 5A ). eNOS S1177 phosphorylation also increased in NTS that received CGS21680 microinjection (1.8Ϯ0.2 versus 1.0Ϯ0.2, PϽ0.05; nϭ6; Figure 5B ). Together, these results support the idea that signal molecule activation by adenosine in the NTS occurs predominantly through the A 2A receptor.
Discussion
Adenosine has been demonstrated to play an important role in cardiovascular modulation in the NTS. 1 Our previous experiments demonstrated that the depressor and bradycardic effects of adenosine in the NTS were blocked by the nonspecific NOS inhibitor N G -nitro-L-arginine methyl ester, which suggested that cardiovascular modulation by adenosine was mediated by activation of NOS and subsequent NO release. 7 Results of the present study confirm and extend our previous observations that eNOS but not nNOS participates in the signal mechanism effect of adenosine on cardiovascular modulation in the NTS. The present data further indicate that ERK1 and ERK2 are the intermediate signal molecules that activate eNOS in the NTS. The present study demonstrated that adenosine-ERK-eNOS signaling exists and plays an important role in modulation of cardiovascular responses to adenosine in the NTS. The ERK cascade is distinguished by a characteristic core cascade of 3 kinases. The first kinase is a so-called MAP kinase kinase kinase (MAPKKK; Raf-1 and B-Raf), which activates the second kinase, a MAP kinase kinase (MAPKK; MEK), by serine/threonine phosphorylation. MEK in turn activates ERK1/2 by phosphorylation of both threonine and tyrosine residues. 25 The ERK cascade was originally discovered to be a critical regulator of cell division and differentiation; however, ERK1 and ERK2, as well as their upstream regulators and many of their downstream targets, are highly expressed in mature neurons. 26 This raises the question of whether ERK1 and ERK2 not only regulate neuronal development but also play regulatory roles in mature neurons in response to various physiological stimuli. A number of studies have suggested the regulatory roles of ERK1/2 in mature neurons. First, ERK1 and ERK2 have been demonstrated to be phosphorylated and activated in neurons in response to excitatory glutamatergic signaling, which controls many forms of synaptic plasticity that are thought to underlie higher brain processes such as learning and memory. 26 Second, activation of ERK1/2 has been identified in central neurons that respond to specific stimuli, such as nociception, unfamiliar taste, synaptic plasticity, and fear memory consolidation. [27] [28] [29] Third, peripheral administration of cholecystokinin and hydralazine can induce ERK1/2 phosphorylation in the NTS. 30, 31 Finally, experiments on rat hippocampus brain slices revealed that a wide variety of G-protein-coupled receptor neurotransmitters, including N-methyl-D-aspartate and adrenergic, dopamine, and muscarinic acetylcholine receptors, activate ERK1/2 by protein kinase A or protein kinase C. 32 All of this suggests the possibility of a broad physiological role for the ERK cascade in the adult central nervous system. Indeed, in the present study, we demonstrated that microinjection of adenosine into the NTS induced ERK1/2 phosphorylation ( Figure 4 ) and that blockade of ERK1/2 activation by PD98059 attenuated the depressor and bradycardic effects of adenosine (Figure 1 ). The present study provides the first evidence to demonstrate the ERK1/2 activation is involved in cardiovascular modulation in the NTS.
It would be interesting to know how adenosine activates ERK1/2 in mature neurons. The activated adenosine A 2A receptor activates adenylyl cyclase, which in turn increases cAMP. 17 Interestingly, cAMP may either inhibit or activate Figure 3 . Quantitative analysis of phospho-eNOS in the NTS after microinjection of adenosine with or without PD98059. A, Immunoblotting revealed that phosphorylated eNOS S1177 was increased in the NTS that received adenosine. Phosphorylation of eNOS was blocked by pretreatment with PD98059 10 minutes before adenosine microinjection. B, Densitometric analysis of immunoblotting of phospho-eNOS S1177 showed that adenosine induced an almost 2-fold increase in phospho-eNOS S1177 compared with the control group. Phospho-eNOS S1177 was decreased by PD98059 pretreatment. Values are shown as meanϮSEM, nϭ6. *PϽ0.05, control vs adenosine group, #PϽ0.01, adenosine vs PD98059ϩadenosine group. C, Immunohistochemistry of the brainstem for phospho-eNOS S1177 demonstrated microinjection of adenosine into the NTS induced eNOS S1177 phosphorylation in situ (c vs d). Pretreatment with PD98059 significantly reduced eNOS S1177 phosphorylation in the NTS (g vs h). PD98059 or vehicle was administered 10 minutes before adenosine. Scale barϭ200 m. ADO indicates adenosine.
ERK1/2 in a cell-specific manner. 33 Emerging new data revealed that the determinant of whether cAMP activates or inhibits the ERK cascade is B-Raf. 34, 35 In B-Rafexpressing cells, cAMP may activate B-Raf by complex mechanisms, and the activated B-Raf subsequently activates the MEK-ERK cascade. 33 A convincing model of how cAMP activates B-Raf is not currently available, but the accumulated data suggest the involvement of RAS, Rap1, Src, protein kinase A, and 14-3-3 proteins. 36 Interestingly, B-Raf is the major RAF isoform expressed in neurons. 37 Therefore, we infer that adenosine activates ERK1/2 in the NTS by activation of the A 2A receptor, an increase in cAMP, activation of B-Raf, and the ensuing phosphorylation and activation of MEK. Signaling molecules that regulate eNOS activity include PI3K/Akt, cyclic nucleotide-dependent kinases (protein kinase A and protein kinase G), protein kinase C, and ERKs. 38 In the present study, we demonstrated that PD98059 inhibited eNOS S1177 phosphorylation ( Figure 3A and 3B ). This result suggests that adenosine may phosphorylate eNOS through activation of MEK/ERK cascades in the NTS. This result is further supported by reports that inhibition of ERK1/2 activation attenuated the eNOS phosphorylation that was induced by estrogen and vascular endothelial growth factor. 39 -41 Although it has been reported for years that ERKs could phosphorylate and activate eNOS, 39 the exact signaling mechanisms that couple the activated ERK1/2 to eNOS activation remained uncertain.
eNOS, originally identified in vascular endothelium, is expressed in several nonendothelial cell types, including neurons of various rat brain regions. Although the physiological functions of eNOS in cardiovascular modulation in the NTS remain controversial, several studies, including the present study, demonstrated that eNOS participates in cardiovascular modulation in the NTS. By reverse-transcription polymerase chain reaction, Waki et al 42 demonstrated that endogenous eNOS mRNA is expressed in the NTS of adult Wistar-Kyoto and spontaneously hypertensive rats. Suppression of the endogenous eNOS by overexpression of dominant-negative eNOS in bilateral NTS increased spontaneous baroreceptor reflex gain in conscious Wistar rats and decreased BP in mature spontaneously hypertensive rats. 42, 43 In the present study, our data revealed that eNOS not only exists in the NTS ( Figure 3A and 3C) but that it also mediates cardiovascular modulation by adenosine (Figure 2 ). Microinjection of adenosine into the NTS induced eNOS phosphorylation in situ ( Figure 3C ).
Scislo et al 21 reported the differential role of NO in regional sympathetic responses to stimulation of NTS A 2A adenosine receptor. They demonstrated that the nNOS-selective antagonist TRIM [1-(2-trifluoromethylphenyl) imidazole; 20 nmol/100 nL] reversed normal depressor responses and significantly attenuated the A 2A receptor-elicited decreases in HR and renal sympathetic nerve activity. They concluded that the hemodynamic and sympathoinhibitory responses caused by stimulation of the NTS A 2A receptor were predominantly mediated by nNOS. 21 Conversely, in the present study, only an eNOS-selective antagonist attenuated the depressor and bradycardic effect of adenosine ( Figure 2B ), whereas the nNOS-specific antagonist did not (Data Supplement Figure II) . TRIM is a potent inhibitor of nNOS (IC 50 of 2.8 mol/L) and a relatively weak inhibitor of eNOS (IC 50 1057.5 mol/L). 44 The concentrations of TRIM used by Scislo and coworkers 21 (200 mmol/L) may have been too high, and therefore, TRIM might have lost its nNOS selectivity and could no longer discriminate which NOS mediated the cardiovascular modulatory effects of adenosine in the NTS. In the present study, we not only demonstrated the pharmacological effects of eNOS inhibitors on cardiovascular parameters (Figure 2) , we also demonstrated eNOS S1177 phosphorylation in situ in the NTS by immunohistochemistry staining ( Figure 3C ). These evidences confirm that cardiovascular modulation by adenosine in the NTS is predominantly through eNOS activation, with only a small contribution, if any, of nNOS.
In conclusion, we present a novel adenosine-ERK-eNOS signaling pathway in the NTS that allows us to dissect the adenosine signaling pathway related to the production of NO in the regulation of BP and HR. Our results suggest a possible interaction between ERK1/2 and eNOS in the NTS. The present data demonstrate that adenosine modulates central cardiovascular control via activation of ERK1/2 and its downstream eNOS.
